| Nome |
# |
|
Cholangiocarcinoma: Epidemiology and risk factors, file e1dcb338-43cc-7715-e053-1705fe0a6cc9
|
212
|
|
Antitumoral Efficacy of Two Turmeric Extracts According to Different Extraction Methods in Hepatocellular Carcinoma Cell Lines, file e1dcb332-d39c-7715-e053-1705fe0a6cc9
|
171
|
|
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments, file e1dcb331-8d2e-7715-e053-1705fe0a6cc9
|
135
|
|
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial, file e1dcb332-77be-7715-e053-1705fe0a6cc9
|
133
|
|
Evolving knowledge in surgical oncology of pancreatic cancer: from theory to clinical practice-a fifteen-year journey at a tertiary referral centre, file cfc93765-2227-4c75-90b5-1473dbc09189
|
131
|
|
Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST), file e1dcb333-0c54-7715-e053-1705fe0a6cc9
|
113
|
|
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept, file e1dcb332-0acc-7715-e053-1705fe0a6cc9
|
112
|
|
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes, file e1dcb33a-1580-7715-e053-1705fe0a6cc9
|
112
|
|
The human microbiomes in pancreatic cancer: Towards evidence-based manipulation strategies?, file e1dcb339-e01b-7715-e053-1705fe0a6cc9
|
106
|
|
Can Current Preoperative Imaging Be Used to Detect Microvascular Invasion of Hepatocellular Carcinoma?, file e1dcb338-7d3f-7715-e053-1705fe0a6cc9
|
105
|
|
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations, file e1dcb32d-4d95-7715-e053-1705fe0a6cc9
|
104
|
|
Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma, file e1dcb333-0c50-7715-e053-1705fe0a6cc9
|
103
|
|
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation, file e1dcb333-a549-7715-e053-1705fe0a6cc9
|
103
|
|
Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look, file e1dcb339-b33d-7715-e053-1705fe0a6cc9
|
91
|
|
Hacking pancreatic cancer: Present and future of personalized medicine, file e1dcb339-8eff-7715-e053-1705fe0a6cc9
|
89
|
|
Occurrence of Bifidobacteriaceae in human hypochlorhydria stomach, file e1dcb32c-4f94-7715-e053-1705fe0a6cc9
|
84
|
|
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer, file e1dcb339-e428-7715-e053-1705fe0a6cc9
|
83
|
|
SUSTAINED COMPLETE RESPONSE OF ADVANCED HEPATOCELLULAR CARCINOMA WITH METRONOMIC CAPECITABINE: A REPORT OF THREE CASES, file e1dcb331-e20b-7715-e053-1705fe0a6cc9
|
81
|
|
The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): A new Pandora's box?, file e1dcb339-9081-7715-e053-1705fe0a6cc9
|
75
|
|
Current strategies and novel therapeutic approaches for metastatic urothelial carcinoma, file e1dcb335-cca9-7715-e053-1705fe0a6cc9
|
74
|
|
Microbiota: Overview and implication in immunotherapy-based cancer treatments, file e1dcb333-e183-7715-e053-1705fe0a6cc9
|
72
|
|
Bone metastases in biliary cancers: A multicenter retrospective survey, file e1dcb332-7913-7715-e053-1705fe0a6cc9
|
71
|
|
Adjuvant treatment in biliary tract cancer, file e1dcb332-c588-7715-e053-1705fe0a6cc9
|
71
|
|
Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST), file e1dcb333-61d4-7715-e053-1705fe0a6cc9
|
68
|
|
Radiotherapy in the management of gist: state of the art and new potential scenarios, file e1dcb32f-1f78-7715-e053-1705fe0a6cc9
|
65
|
|
Occupational exposure to asbestos and risk of cholangiocarcinoma: a population-based case-control study in four Nordic countries, file e1dcb331-1025-7715-e053-1705fe0a6cc9
|
65
|
|
Recent advances of immunotherapy for biliary tract cancer, file e1dcb339-c814-7715-e053-1705fe0a6cc9
|
65
|
|
Assessing the impact of COVID-19 on liver cancer management (CERO-19), file e1dcb339-c4a7-7715-e053-1705fe0a6cc9
|
63
|
|
The human microbiota and prostate cancer: Friend or foe?, file e1dcb335-5911-7715-e053-1705fe0a6cc9
|
62
|
|
Searching for novel multimodal treatments in oligometastatic pancreatic cancer, file e1dcb336-bf6d-7715-e053-1705fe0a6cc9
|
62
|
|
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements, file e1dcb336-fb0d-7715-e053-1705fe0a6cc9
|
61
|
|
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes, file ea50ea63-b407-4ec2-8b82-fbae42be898f
|
59
|
|
Association between asbestos exposure and pericardial and tunica vaginalis testis malignant mesothelioma: A case–control study and epidemiological remarks, file e1dcb339-a858-7715-e053-1705fe0a6cc9
|
58
|
|
Non-coding RNAs as predictive biomarkers to current treatment in metastatic colorectal cancer, file e1dcb330-37a8-7715-e053-1705fe0a6cc9
|
57
|
|
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study, file e1dcb332-ae20-7715-e053-1705fe0a6cc9
|
57
|
|
Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene., file e1dcb330-b27a-7715-e053-1705fe0a6cc9
|
56
|
|
Non-alcoholic steatohepatitis as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role, file e1dcb336-0cd3-7715-e053-1705fe0a6cc9
|
55
|
|
Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma, file e1dcb333-e34c-7715-e053-1705fe0a6cc9
|
53
|
|
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster, file e1dcb336-6e55-7715-e053-1705fe0a6cc9
|
51
|
|
Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis, file e1dcb336-4552-7715-e053-1705fe0a6cc9
|
46
|
|
Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review, file e1dcb339-b374-7715-e053-1705fe0a6cc9
|
46
|
|
Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study, file e1dcb32e-f1a5-7715-e053-1705fe0a6cc9
|
45
|
|
null, file e1dcb338-36d9-7715-e053-1705fe0a6cc9
|
41
|
|
First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: “And Yet It Moves!”, file e1dcb339-a8b2-7715-e053-1705fe0a6cc9
|
39
|
|
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies, file e1dcb32f-51da-7715-e053-1705fe0a6cc9
|
37
|
|
Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma, file e1dcb339-a6e9-7715-e053-1705fe0a6cc9
|
36
|
|
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges, file e1dcb339-91a7-7715-e053-1705fe0a6cc9
|
34
|
|
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma, file e1dcb339-a75f-7715-e053-1705fe0a6cc9
|
33
|
|
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives, file e1dcb339-c812-7715-e053-1705fe0a6cc9
|
33
|
|
Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. A review of the literature and a long-standing experience of a referral center, file e1dcb32e-f9e2-7715-e053-1705fe0a6cc9
|
30
|
|
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report, file e1dcb336-8a4c-7715-e053-1705fe0a6cc9
|
30
|
|
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?, file e1dcb339-875b-7715-e053-1705fe0a6cc9
|
30
|
|
Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions, file e1dcb339-aee5-7715-e053-1705fe0a6cc9
|
30
|
|
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS, file e1dcb336-d2ca-7715-e053-1705fe0a6cc9
|
29
|
|
Microbiota and prostate cancer, file e1dcb339-b6f3-7715-e053-1705fe0a6cc9
|
29
|
|
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?, file e1dcb337-4b0e-7715-e053-1705fe0a6cc9
|
27
|
|
TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricks, file e1dcb339-ba7a-7715-e053-1705fe0a6cc9
|
27
|
|
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression, file e1dcb33a-0f68-7715-e053-1705fe0a6cc9
|
26
|
|
Asbestos and Intrahepatic Cholangiocarcinoma, file e1dcb339-aecc-7715-e053-1705fe0a6cc9
|
24
|
|
Association between asbestos exposure and pericardial and tunica vaginalis testis malignant mesothelioma: A case–control study and epidemiological remarks, file e1dcb336-cced-7715-e053-1705fe0a6cc9
|
23
|
|
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience, file e1dcb339-d452-7715-e053-1705fe0a6cc9
|
23
|
|
Heterotopic segmental liver transplantation on splenic vessels after splenectomy with delayed native hepatectomy after graft regeneration: A new technique to enhance liver transplantation, file 702ea3d2-da1a-449a-bc3d-dfce3a6aea1e
|
21
|
|
Critical diagnostic delay associated with unusual presentation of hepatocellular carcinoma (Hcc) with orbital metastases: A case report, file e1dcb339-aee9-7715-e053-1705fe0a6cc9
|
21
|
|
Evolution of the experimental models of cholangiocarcinoma, file e1dcb339-a4cf-7715-e053-1705fe0a6cc9
|
17
|
|
Nivolumab: an investigational agent for the treatment of biliary tract cancer, file e1dcb339-e2be-7715-e053-1705fe0a6cc9
|
17
|
|
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index, file e1dcb339-824a-7715-e053-1705fe0a6cc9
|
16
|
|
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS, file e1dcb339-a5b3-7715-e053-1705fe0a6cc9
|
16
|
|
Pd‐l1, tmb, msi, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer, file e1dcb339-a6f6-7715-e053-1705fe0a6cc9
|
16
|
|
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures, file e1dcb339-e735-7715-e053-1705fe0a6cc9
|
16
|
|
Mutational Landscape of Cholangiocarcinoma According to Different Etiologies: A Review, file 8f7bf140-f43d-4c01-bbcc-bfbd0ed86803
|
15
|
|
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases., file e1dcb32d-4770-7715-e053-1705fe0a6cc9
|
15
|
|
Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report., file e1dcb336-90bc-7715-e053-1705fe0a6cc9
|
15
|
|
Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations?, file 9a1f576b-43b9-4c64-8301-59b0598a6a64
|
13
|
|
The Human Microbiomes in Pancreatic Cancer: Towards Evidence-Based Manipulation Strategies?, file e1dcb339-badb-7715-e053-1705fe0a6cc9
|
13
|
|
Identifying ethical values for guiding triage decisions during the COVID-19 pandemic: an Italian ethical committee perspective using Delphi methodology, file e1dcb339-8e22-7715-e053-1705fe0a6cc9
|
12
|
|
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue, file e1dcb339-e426-7715-e053-1705fe0a6cc9
|
12
|
|
Current and novel therapeutic opportunities for systemic therapy in biliary cancer, file e1dcb339-e507-7715-e053-1705fe0a6cc9
|
12
|
|
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study, file ddfe71b8-a41c-419e-aa6a-fb3b2406c9d7
|
11
|
|
Combination therapy of dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer, file e1dcb339-807f-7715-e053-1705fe0a6cc9
|
11
|
|
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab, file e1dcb339-dd11-7715-e053-1705fe0a6cc9
|
11
|
|
Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future, file e1dcb339-874f-7715-e053-1705fe0a6cc9
|
10
|
|
Experimental HER2- targeted therapies for biliary tract cancer, file e1dcb339-aa81-7715-e053-1705fe0a6cc9
|
10
|
|
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations, file e1dcb339-b6f5-7715-e053-1705fe0a6cc9
|
10
|
|
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation., file e1dcb330-f623-7715-e053-1705fe0a6cc9
|
9
|
|
Precision oncology in cholangiocarcinoma: current issues in clinical trial design and access to targeted therapies, file e1dcb339-b745-7715-e053-1705fe0a6cc9
|
9
|
|
Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer, file f4d562a8-2400-49f7-b695-fee2c4fd3fad
|
9
|
|
Identifying ethical values for guiding triage decisions during the COVID-19 pandemic: an Italian ethical committee perspective using Delphi methodology, file 4c6bf437-ac77-4012-8cb0-d253ea4cab7a
|
8
|
|
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma, file e1dcb339-0e34-7715-e053-1705fe0a6cc9
|
8
|
|
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2, file e1dcb339-7cfc-7715-e053-1705fe0a6cc9
|
8
|
|
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index, file e1dcb339-7ddd-7715-e053-1705fe0a6cc9
|
8
|
|
BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care, file e1dcb339-c80c-7715-e053-1705fe0a6cc9
|
8
|
|
Novel targeted therapies for advanced cholangiocarcinoma, file e1dcb339-e160-7715-e053-1705fe0a6cc9
|
8
|
|
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab, file 9a48d0cf-c8bd-46e2-8dff-a35bd40002f6
|
7
|
|
Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link, file b934f2a6-c4eb-488a-a89c-6d3edd35c33e
|
7
|
|
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study, file d58a4c54-ed9a-49b7-8acf-ba0c79a278e4
|
7
|
|
Hypothesis on the possible relevance of the immunogenic cell death in the treatment of gestational trophoblastic neoplasms, file e1dcb338-4267-7715-e053-1705fe0a6cc9
|
7
|
|
Systemic adjuvant treatment in hepatocellular carcinoma: Tempted to do something rather than nothing, file e1dcb339-e541-7715-e053-1705fe0a6cc9
|
7
|
|
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis, file e1dcb333-cd9f-7715-e053-1705fe0a6cc9
|
6
|
|
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2, file e1dcb339-91b0-7715-e053-1705fe0a6cc9
|
6
|
|
Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?, file e1dcb339-aa0b-7715-e053-1705fe0a6cc9
|
6
|
| Totale |
4.544 |